Cadrenal Therapeutics Financials - Benzinga

Cadrenal Therapeutics Inc

CVKDNASDAQ

Trade with Public

Trade with Public

$1.07

-0.05-4.46%

At close: Sep 18, 5:00 PM EST

$1.10

0.032.8%

After Hours: Sep 18, 7:27 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Stock Report

Cadrenal Therapeutics Financials

Cadrenal Therapeutics (CVKD) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Cadrenal Therapeutics Q2 EPS $(1.14) Beats $(1.42) Estimate

Benzinga Newsdesk

PRO
Cadrenal Therapeutics Q1 EPS $(1.04) Beats $(1.62) Estimate

Cadrenal Therapeutics (NASDAQ:CVKD) reported quarterly losses of $(1.04) per share which beat the analyst consensus estimate of $(1.62) by 35.8 percent. This is a 50.24 percent increase over losses of $(2.09) per share

Benzinga Newsdesk

PRO
Cadrenal Therapeutics Q4 EPS $(1.41) Misses $(1.18) Estimate

Cadrenal Therapeutics (NASDAQ:CVKD) reported quarterly losses of $(1.41) per share which missed the analyst consensus estimate of $(1.18) by 19.49 percent. This is a 49.64 percent increase over losses of $(2.80) per

Benzinga Newsdesk

PRO
Cadrenal Therapeutics Q3 EPS $(1.31) Beats $(1.53) Estimate

Cadrenal Therapeutics (NASDAQ:CVKD) reported quarterly losses of $(1.31) per share which beat the analyst consensus estimate of $(1.53) by 14.21 percent. This is a 39.91 percent increase over losses of $(2.18) per share

Benzinga Newsdesk

PRO
Cadrenal Therapeutics Q2 EPS $(1.87) Misses $(1.60) Estimate

Cadrenal Therapeutics (NASDAQ:CVKD) reported quarterly losses of $(1.87) per share which missed the analyst consensus estimate of $(1.60) by 17.09 percent. This is a 16.89 percent increase over losses of $(2.25) per

Benzinga Newsdesk

PRO
Cadrenal Therapeutics Q1 EPS $(2.09) Misses $(1.25) Estimate

Cadrenal Therapeutics (NASDAQ:CVKD) reported quarterly losses of $(2.09) per share which missed the analyst consensus estimate of $(1.25) by 67.2 percent. This is a 39.33 percent decrease over losses of $(1.50) per share

Benzinga Newsdesk